NCT00333021已完成3 期
Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in Prevention of Venous Thromboembolism (VTE) After Abdominal Surgery
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 127
- 试验地点
- 18
- 主要终点
- Incidence of Venous thromboembolism and Major bleeding
研究概览
简要总结
This study is phase 3 study for prevention of VTE in patients with abdominal surgery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients aged >=40 years undergoing the following abdominal (diaphragm to pelvic floor) surgery under general anesthesia lasting more than 45 minutes.
- •General or urologic surgery
- •Cancer surgery
- •Gynecologic surgery
- •Radical surgery for pelvic malignancy
排除标准
- •Active, clinically significant bleeding Thrombocytopenia Body weight <40kg
结局指标
主要结局
Incidence of Venous thromboembolism and Major bleeding
时间窗: Throughout entire study
次要结局
- Incidence of Pulmonary embolism Incidence of Deep vein thrombosis Incidence of symptomatic Venous thromboembolism(Throughout entire study)
研究者
研究点 (18)
Loading locations...
相似试验
已完成
3 期
The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese PatientsThrombosis, VenousNCT00911157GlaxoSmithKline39
已完成
3 期
The Treatment of Acute Pulmonary Thromboembolism (PE) of GSK576428 (Fondaparinux Sodium) in Japanese PatientsEmbolism, PulmonaryNCT00981409GlaxoSmithKline41
已完成
3 期
Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)Thrombosis, VenousNCT00320398GlaxoSmithKline114
已完成
3 期
Hip Fracture Study of GSK576428 (Fondaparinux Sodium)ThromboembolismNCT00320424GlaxoSmithKline48
已完成
2 期
Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)Myocardial IschemiaMyocardial InfarctionAtherosclerosisNCT00684203Merck Sharp & Dohme LLC120